Skip to main content

Human Papillomavirus Infections

2
Pipeline Programs
6
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
4100%
+ 2 programs with unclassified modality

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Angel Pharmaceuticals
Angel PharmaceuticalsChina - Zhejiang
1 program
1
Nonavalent HPV vaccinePhase 4Vaccine1 trial
Active Trials
NCT05334706Recruiting69Est. Dec 2026
Nordic Pharma
Nordic PharmaFrance - Paris
1 program
1
Ad26.HPV16Phase 1/2
MSD
MSDIreland - Ballydine
1 program
GARDASIL™ Vaccine Impact in Population Study (V501-033)N/AVaccine1 trial
Active Trials
NCT01077856Completed54,516Est. Dec 2014
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
GARDASIL™ Vaccine Impact in Population Study (V501-033)N/AVaccine
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
GARDASIL™ Vaccine Impact in Population Study (V501-033)N/AVaccine
Bavarian Nordic
Bavarian NordicDenmark - Kvistgard
1 program
Ad26.HPV16PHASE_1_21 trial
Active Trials
NCT03610581Terminated9Est. Oct 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Angel PharmaceuticalsNonavalent HPV vaccine
Bavarian NordicAd26.HPV16
MSDGARDASIL™ Vaccine Impact in Population Study (V501-033)

Clinical Trials (3)

Total enrollment: 54,594 patients across 3 trials

NCT05334706Angel PharmaceuticalsNonavalent HPV vaccine

A Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive Women After Vaccination With 9vHPV (RIFT-HPV)

Start: Sep 2022Est. completion: Dec 202669 patients
Phase 4Recruiting
NCT03610581Bavarian NordicAd26.HPV16

Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix

Start: Sep 2018Est. completion: Oct 20209 patients
Phase 1/2Terminated
NCT01077856MSDGARDASIL™ Vaccine Impact in Population Study (V501-033)

GARDASIL™ Vaccine Impact in Population Study (V501-033)

Start: May 2007Est. completion: Dec 201454,516 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 54,594 patients
Vaccine is the dominant modality (100% of programs)
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.